YMRC
VRTX icon

Yorktown Management & Research Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Yorktown Management & Research Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,900
Closed -$220K – 434
2013
Q3 		$220K Hold
2,900
– – 0.05% 301
2013
Q2 		$232K Buy
+2,900
New +$214K 0.05% 235

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Yorktown Management & Research Company's VRTX Position: Q4 2013 in Review

Yorktown Management & Research Company sold out of Vertex Pharmaceuticals (VRTX) in Q4 2013, closing a stake of 2,900 shares — an estimated $220K sold.

Yorktown Management & Research Company first reported a position in VRTX in Q2 2013 and held it in 2 quarters. The position peaked at $232K in Q2 2013. 387 funds tracked by Wall St. Rank hold VRTX as of Q4 2013.

  • Yorktown Management & Research Company reported no remaining Vertex Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Yorktown Management & Research Company sold 2,900 Vertex Pharmaceuticals shares in Q4 2013, an estimated $220K.
  • Yorktown Management & Research Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Yorktown Management & Research Company's Vertex Pharmaceuticals position peaked at $232K in Q2 2013.
  • 387 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2013.

Based on Yorktown Management & Research Company's 13F filing for Q4 2013, filed 22 Jan 2014.